We have carefully reviewed the article by Ilay Shani and Avishay Elis, “The Approach to Triglyceride Levels in Patients with Coronary Heart Disease,” and commend the authors for their comprehensive evaluation of triglyceride management in a large cohort of patients with coronary heart disease (CHD) admitted for anginal syndromes [1]. While the authors acknowledge the retrospective design and the lack of pharmacologic omega-3 agent data as limitations, additional concerns deserve consideration to provide readers with a balanced interpretation of the findings.
